Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides

Lancet

Volumn 355, Issue 9199, 2000, Pages 192-197

  Soto, Claudio ^g   Kascsak, Richard J ^b   Saborío, Gabriela P ^a   Aucouturier, Pierre ^g   Wisniewski, Thomas ^g   Prelli, Frances ^g   Kascsak, Regina ^b   Mendez, Enrique ^c   Harris, David A ^d   Ironside, James ^e   Tagliavini, Fabrizio ^f   Carp, Richard I ^b   Frangione, Blas ^g  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f DEPARTMENT OF NEUROSURGERY   (Italy)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; PRION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SPONGIOSIS; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE MODEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE; SCRAPIE; SEQUENCE HOMOLOGY; SYMPTOM;

EID: 0034650634     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)11419-3     Document Type: Article

References (30)

1. Prusiner S.B. Prions. Proc Natl Acad Sci USA. 95:1998;13363-13383.
2. Haywood A.M. Transmissible spongiform encephalopathies. N Engl J Med. 337:1997;1821-1828.
3. Carp R.I., Ye X., Kascsak R.J., Rubenstein R. The nature of the scrapie agent: biological characteristics of scrapie in different scrapie strain-host combinations. Ann NY Acad Sci. 724:1994;221-234.
4. Prusiner S.B., Scott M., DeArmond S.J., Cohen F.E. Prion protein biology. Cell. 93:1998;337-348.
5. Dickinson A.G., Outram G.W. Genetic aspects of unconventional virus infections: the basis of the virino hypothesis. Ciba Foundation Symposium. 135:1988;63-83.
6. Cohen F.E., Prusiner S.B. Pathologic conformations of prion proteins. Ann Rev Biochem. 67:1998;793-819.
7. De Gioia L., Selvaggini C., Ghibaudi E.et al. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. J Biol Chem. 269:1994;7859-7862.
8. Zhang H., Kaneko K., Nguyen J.T.et al. Conformational transitions in peptides containing two putative alpha-helices of the prion protein. J Med Biol. 250:1995;514-526.
9. Chabry J., Caughey B., Chesebro B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem. 273:1998;13203-13207.
10. Li S-C., Goto N.K., Williams K.A., Deber C.M. Alpha-helical but not beta-sheet propensity of proline is determined by peptide environment. Proc Natl Acad Sci USA. 93:1996;6676-6681.
11. Kascsak R.J., Fersko R., Pulgiano D., Rubenstein R., Carp R.I. Immunodiagnosis of prion diseases. Immunol Invest. 26:1997;259-265.
12. Perczel A., Park K., Fasman G.D. Analysis of circular dichroism spectrum of proteins using the convex constraint algorithim. Anal Biochem. 203:1992;83-93.
13. Narwa R., Harris D.A. Prion proteins carrying pathogenic mutations are resistant to phospholipase cleavage of their glycolipid anchors. Biochemistry. 38:1999;8770-8777.
14. Kimberlin R.H. Experimental scrapie in the mouse: a review of an important model disease. Sci Prog. 63:1976;461-481.
15. Carp R.I., Callahan S.M., Sersen E.A., Moretz R.C. Preclinical changes in weight of scrapie infected mice as a function of scrapie agent-mouse strain combination. Intervirology. 21:1984;61-69.
16. Soto C., Kindy M.S., Baumann M., Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun. 226:1996;672-680.
17. Gassett M., Baldwin M., Fletterick R.J., Prusiner S.B. Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. Proc Natl Acad Sci USA. 90:1993;1-5.
18. Jackson M., Mantsch H.H. The use and misuse of fourier transform infrared spectroscopy for analysis of protein secondary structure. Crit Rev Biochem. 30:1995;95-120.
19. Soto C., Sigurdsson E.M., Morelli L., Kumar R.A., Castano E.M., Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 4:1998;822-826.
20. Soto C. β-amyloid disrupting drugs: potential in the treatment of Alzheimer's disease. CNS Drugs. 12:1999;347-356.
21. Caughey B., Raymond G.J., Bessen R.A. Strain-dependent differences in β-sheet conformation of abnormal prion protein. J Biol Chem. 273:1998;32230-32235.
22. Safar J., Wille H., Itri V.et al. Eight prion strains have PrPsc molecules with different conformations. Nat Med. 4:1998;1157-1165.
23. Aucouturier P., Kascsak R.J., Frangione B., Wisniewski T. Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt-Jakob disease. Neurosci Lett. 274:1999;33-36.
24. Brown P. A therapeutic panorama of the spongiform encephalopathies. Antiviral Chem Chemother. 1:1990;75-83.
25. Adjou K.T., Deslys J.P., Demainmay R., Seman M., Dormont D. Prospect for the pharmacological treatment of human prion diseases. CNS Drugs. 10:1998;83-89.
26. Fauchere J.L., Thurieau C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv Drug Res. 23:1992;127-159.
27. Moore G.J. Designing peptide mimetics. Trends Pharmacol Sci. 15:1994;124-129.
28. Will R.G., Ironside J.W., Zeidler M.et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 347:1996;925.
29. Bruce M.E., Will R.G., Ironside J.W., McConnell I., Drummond D., Suttie A. Transmissions to mice indicate that new variant CJD is caused by BSE agent. Nature. 389:1997;498-501.
30. Cousens S.N., Vynnycky E., Zeidler M., Will R.G., Smith R.G. Predicting the CJD epidemic in humans. Nature. 385:1997;197-198.